NIH Reporter #3R01CA164719-12S2

Solicitation for anti-cancer vaccine development targeting fluke infection proteins

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), is seeking proposals for the development and testing of an anti-cancer vaccine targeting proteins essential to the parasite Opisthorchis viverrini. - Government Buyer: - National Cancer Institute (NCI), National Institutes of Health (NIH) - Scope of Work: - Vaccine development and testing against Opisthorchis viverrini - Protein analysis and characterization - Animal model studies to evaluate vaccine efficacy - Products/Services Requested: - Vaccine development and testing (1 lot) - Protein analysis and characterization (1 lot) - Animal model studies (1 lot) - Unique Requirements: - Focus on reducing fluke burden and cholangiocarcinoma incidence - Use of innovative gene knockout techniques - No specific OEMs or vendors named; open to qualified research organizations - Estimated Contract Value: - $139,050 - Funding Opportunity: - NIH PA-20-185 - Period of Performance: - One year duration - Annual project cycle - No specific product part numbers or commercial products; all services are custom research and development.

Description

This solicitation is for the development and testing of a vaccine targeting proteins essential to the parasite Opisthorchis viverrini to reduce fluke burden and cholangiocarcinoma incidence. The project includes protein analysis, characterization, and animal model studies. It involves innovative gene knockout techniques and vaccine development. The funding is provided by the National Cancer Institute, NIH, and the project duration is from September 1, 2025, to August 31, 2026.

View original listing